Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Stock analysts at Jefferies Financial Group upped their FY2018 EPS estimates for shares of Intercept Pharmaceuticals in a research note issued on Wednesday, October 31st. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will earn ($10.44) per share for the year, up from their previous forecast of ($11.37). Jefferies Financial Group also issued estimates for Intercept Pharmaceuticals’ Q4 2018 earnings at ($2.55) EPS and FY2019 earnings at ($9.69) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, topping the consensus estimate of ($2.65) by $0.47. The business had revenue of $47.00 million for the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted ($2.89) earnings per share.
ICPT has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush reaffirmed a “buy” rating and set a $203.00 price objective (down from $217.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub downgraded shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. ValuEngine raised shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $115.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $139.88.
Intercept Pharmaceuticals stock opened at $110.13 on Monday. Intercept Pharmaceuticals has a fifty-two week low of $51.05 and a fifty-two week high of $133.74. The company has a market capitalization of $3.24 billion, a PE ratio of -7.66 and a beta of -1.08. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.
In other Intercept Pharmaceuticals news, insider David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $96.32, for a total value of $192,640.00. Following the completion of the sale, the insider now directly owns 41,152 shares in the company, valued at $3,963,760.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 11,101 shares of company stock valued at $1,177,128 over the last quarter. Corporate insiders own 4.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HL Financial Services LLC lifted its stake in Intercept Pharmaceuticals by 4.0% in the second quarter. HL Financial Services LLC now owns 12,499 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 483 shares during the last quarter. Strs Ohio acquired a new stake in Intercept Pharmaceuticals in the third quarter valued at approximately $126,000. Federated Investors Inc. PA lifted its stake in Intercept Pharmaceuticals by 17.9% in the second quarter. Federated Investors Inc. PA now owns 6,765 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 1,025 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Intercept Pharmaceuticals by 18.0% in the second quarter. Janney Montgomery Scott LLC now owns 8,422 shares of the biopharmaceutical company’s stock worth $707,000 after buying an additional 1,285 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Intercept Pharmaceuticals by 12.6% in the third quarter. Bank of Montreal Can now owns 12,363 shares of the biopharmaceutical company’s stock worth $1,562,000 after buying an additional 1,385 shares during the last quarter. Hedge funds and other institutional investors own 70.07% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Featured Story: What is insider trading?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.